Erika Roberts

1 month ago | outsourcedpharma.com | Erika Roberts |Louis Garguilo

By Erika Roberts, ELR Lab Services LLC The pharmaceutical industry is undergoing a seismic shift, driven by the integration of artificial intelligence (AI) into manufacturing and quality control processes. This transition, often referred to as Pharma 4.0, will lead to a fundamental evolution in the skillsets of quality assurance and control personnel.

Aug 28, 2024 | outsourcedpharma.com | Louis Garguilo |Erika Roberts |Daniel L. Kirschner

Webinar: Advances in Oral GLP-1 Analogs for Obesity: Market Insights, Challenges, and Delivery StrategiesJoin us on September 12, 2024, at 11:00am EDT as we explore the impact of oral GLP-1 analogs on obesity treatment. We’ll cover their role in improving patient adherence and market expansion while addressing challenges like stability and bioavailability. Key topics include the significance of GLP-1 analogs, market growth, and innovative delivery strategies. Click here to learn more.

Aug 13, 2024 | pharmaceuticalonline.com | Erika Roberts

By Erika L. Roberts, ELR Lab Services LLC Remember those sci-fi movies where scientists manipulated 3D models of molecules with a wave of their hand? Well, it's not entirely fiction anymore. Virtual reality (VR) and extended reality (XR) are making their way into pharmaceutical manufacturing, promising to revolutionize how we design, train, and operate in this highly regulated sector.

May 16, 2024 | meddeviceonline.com | Erika Roberts |Michael Moussourakis |Jeff Phillips |Stacy Silverstein

Get the latest industry news and expert insights delivered straight to your inbox! Newsletter | May 16, 2024 The FDA recently announced that they have seen an increase in the number of entities that contract out testing or services where the data provided by said firms was fabricated, duplicated, or just deemed “unreliable.” Here's what you can do.

Apr 23, 2024 | laboratorynetwork.com | Erika Roberts |Tim Sandle

The FDA recently announced that they have seen an increase in the number of entities that contract out testing or services where the data provided by said firms was fabricated, duplicated, or just deemed “unreliable.” Here's what you can do.